http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 Jun 2025 17:57:01 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Philogen+subsidiary+and+Bristol-Myers+%28BMY%29+subsidiary+announce+licensing+agreement+for+OncoACP3/24921695.html <p>Philochem AG ("Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p><p align="justify">OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated http://www.streetinsider.com/Corporate+News/Philogen+subsidiary+and+Bristol-Myers+%28BMY%29+subsidiary+announce+licensing+agreement+for+OncoACP3/24921695.html Tue, 10 Jun 2025 17:57:01 -0400 BMY PHIL http://www.streetinsider.com/Corporate+News/Philogen+subsidiary+and+Bristol-Myers+%28BMY%29+subsidiary+announce+licensing+agreement+for+OncoACP3/24921695.html <p>Philochem AG ("Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p><p align="justify">OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated http://www.streetinsider.com/Corporate+News/Philogen+subsidiary+and+Bristol-Myers+%28BMY%29+subsidiary+announce+licensing+agreement+for+OncoACP3/24921695.html Tue, 10 Jun 2025 17:57:01 -0400 BMY PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Press+Releases/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html <ul type="disc"><li style="text-align:justify;"><em>Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales </em><br/><br/></li></ul> <p align="justify">OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG (&quot;Philochem”), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. (“RayzeBio”), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio.</p> http://www.streetinsider.com/Globe+Newswire/Philochem+AG+Announces+the+Licensing+of+Worldwide+Rights+to+OncoACP3%2C+a+novel+Radiopharmaceutical+Therapeutic+and+Diagnostic+Agent+targeting+Prostate+Cancer%2C+to+RayzeBio%2C+a+Bristol-Myers+Squibb+Compan/24921693.html Tue, 10 Jun 2025 17:55:00 -0400 A.07414818 A.09267050 A.24892493 A.50200364 A.50202482 BMY O.00000283 O.00806440 O.03227691 O.07129480 O.08134492 O.59331052 PHIL